1. Home
  2. EMBC vs ACIU Comparison

EMBC vs ACIU Comparison

Compare EMBC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Embecta Corp.

EMBC

Embecta Corp.

HOLD

Current Price

$3.37

Market Cap

207.1M

Sector

Health Care

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.30

Market Cap

221.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMBC
ACIU
Founded
1924
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
207.1M
221.9M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
EMBC
ACIU
Price
$3.37
$2.30
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$18.50
$10.00
AVG Volume (30 Days)
2.4M
256.1K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
6.88%
N/A
EPS Growth
20.90
N/A
EPS
0.67
N/A
Revenue
N/A
N/A
Revenue This Year
$1.17
$706.75
Revenue Next Year
N/A
$321.13
P/E Ratio
$5.13
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.77
$2.03
52 Week High
$15.55
$4.00

Technical Indicators

Market Signals
Indicator
EMBC
ACIU
Relative Strength Index (RSI) 48.77 43.52
Support Level $3.03 $2.15
Resistance Level $3.48 $2.66
Average True Range (ATR) 0.14 0.14
MACD 0.06 -0.02
Stochastic Oscillator 66.27 34.31

Price Performance

Historical Comparison
EMBC
ACIU

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: